These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32099679)

  • 1. Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-DRE Urine Improves Diagnosis of Prostate Cancer in Chinese Population.
    Ye LF; He S; Wu X; Jiang S; Zhang RC; Yang ZS; Chen FW; Pan DL; Li D; Li G
    Prostate Cancer; 2020; 2020():3964615. PubMed ID: 32099679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study.
    Li Y; Ji J; Lyu J; Jin X; He X; Mo S; Xu H; He J; Cao Z; Chen X; Xu Y; Wang L; Wang F
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
    Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
    Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
    Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
    Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
    van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
    Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
    Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
    Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
    Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
    BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
    Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
    Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.
    Albitar M; Ma W; Lund L; Albitar F; Diep K; Fritsche HA; Shore N
    J Cancer; 2016; 7(3):297-303. PubMed ID: 26918043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
    Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
    Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.